Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions

Biomedicines

Jennifer Tan¹  Steven David¹  Lama Karroum¹  Shankar Siva¹  Sherene Loi²  Peter Savas² 

[1] Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia;The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3000, Australia;

关键词: SABR;    breast cancer;    immunotherapy;    stereotactic radiotherapy;    immuno-oncology;   

DOI  :  10.3390/biomedicines10040821

来源: DOAJ

【 摘 要 】

The role of radiotherapy and immunotherapy with immune checkpoint inhibitors (ICI) is of emerging interest in many solid tumours, including breast cancer. There is increasing evidence that the host’s immune system plays an important role in influencing the response to treatment and prognosis in breast cancer. Several pre-clinical studies and clinical trials have reported on the ‘abscopal effect—regression of distant untreated tumour sites, mediated by an immunological response following ionizing radiation to a targeted tumour site. Stereotactic Ablative Body Radiotherapy (SABR) is a non-invasive technique used to augment various immune responses with an ablative tumoricidal dose when compared to conventional radiotherapy. SABR is characterized by typically 1–5 precision radiotherapy treatments that simultaneously deliver a high dose, whilst sparing normal tissues. Following SABR, there is evidence of systemic immune activation in patients with increased PD1 expression on CD8⁺ and CD4⁺ T cells. Studies continue to focus on metastatic triple-negative disease, a highly immunogenic subtype of breast cancer with poor prognosis. In this review, we discuss the immunological effect of SABR, alone and in combination with immunotherapy, and the importance of dose and fractionation. We also propose future strategies for treating oligometastatic disease, where this approach may be most useful for producing durable responses.

【 授权许可】

Unknown